Statistics on Biotechnology Use  
Total Sectors
Biotechnology indicators by execution sector.
Units: Specified in each variable

;Total;Companies;Public Administration;Higher Education;NPPI;
Units carrying out R&D in Biotechnology;1,636;113;68;1,444;11;
% Units by type of biotechnology used: Genetic Code;37.2;87.6;94.1;30.7;27.3;
% Units by type of biotechnology used: Functional Units;43.5;86.7;95.6;37.6;54.5;
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;27.6;72.6;80.9;21.3;63.6;
% Units by type of biotechnology used: Bioprocesses;53.6;65.5;91.2;50.9;54.5;
% Units by type of biotechnology used: Subcellular Organisms;13.9;55.8;64.7;8.1;36.4;
% Units by type of biotechnology used: Bioinformatics;28.7;71.7;83.8;22.6;36.4;
% Units by type of biotechnology used: Nanobiotechnology;15.5;53.1;73.5;9.8;18.2;
% Units by type of biotechnology used: Other;15.7;7.1;7.3;16.9;9.1;
Units in which biotechnology activities are: Main and/or exclusive;676;35;5;629;7;
Units in which biotechnology activities are: A secondary business line;347;36;47;262;2;
Units in which biotechnology activities are: A necessary tool for production;613;42;16;553;2;
% Units by final application areas of biotechnology use: Human Health;48.7;76.1;92.7;44.3;72.7;
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;17.8;18.6;61.8;15.8;9.1;
% Units by final application areas of biotechnology use: Food Products;32.4;26.6;82.3;30.7;0.0;
% Units by final application areas of biotechnology use: Agriculture and Forestry;26.4;21.2;67.7;24.9;18.2;
% Units by final application areas of biotechnology use: Environment;19.8;23.9;75.0;16.9;9.1;
% Units by final application areas of biotechnology use: Industry;15.2;18.6;66.2;12.6;9.1;
R&D personnel in Biotechnology (PP);50,084;15,563;16,597;17,743;181;
R&D personnel in Biotechnology (PP): Research personnel;32,396;9,798;13,026;9,445;127;
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;17,688;5,765;3,571;8,298;54;
R&D personnel in Biotechnology (PP). Women;28,401;9,804;8,578;9,907;112;
R&D personnel in Biotechnology (PP). Women: Research personnel;17,461;5,851;6,435;5,104;71;
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;10,939;3,953;2,143;4,802;41;
R&D personnel in Biotechnology (FTE);35,301.2;11,442.1;10,721.9;12,993.4;143.8;
R&D personnel in Biotechnology (FTE): Research personnel;22,324.6;6,766.8;8,386.7;7,069.9;101.2;
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;12,976.7;4,675.3;2,335.2;5,923.6;42.6;
R&D personnel in Biotechnology (FTE). Women;20,474.8;7,280.8;5,633.9;7,471.8;88.3;
R&D personnel in Biotechnology (FTE). Women: Research personnel;12,176.5;4,080.5;4,171.9;3,870.1;54.0;
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;8,298.2;3,200.3;1,462.0;3,601.6;34.3;
Expenditure on internal R&D in Biotechnology (thousands of euros);2,565,367;775,164;554,906;1,223,801;11,496;
1) By type of expenditure: Current expenditure;2,359,528;727,099;513,043;1,108,189;11,197;
1.1) Labour expenditure of research personnel;950,162;267,235;318,977;360,922;3,027;
1.2) Labour expenditure of technical and auxiliary personnel;421,784;128,800;71,268;220,540;1,176;
1.3) Other current expenditure;987,583;331,063;122,798;526,727;6,994;
2) By type of expenditure: Capital expenditure;205,839;48,066;41,862;115,612;299;
2.1) Land and buildings;30,577;6,521;7,162;16,843;52;
2.2) Equipment and tools;136,544;39,416;33,362;63,527;239;
2.3) Acquisition of specific R&D software;7,117;1,945;1,211;3,959;3;
2.4) Other R&D-specific IP products;31,601;184;128;31,284;5;
1.1) By origin of funds: Own funds;1,030,214;78,546;90,048;860,603;1,016;
1.2) By origin of funds: Funds from the Business sector;277,770;115,144;27,808;128,002;6,816;
1.3) By origin of funds: Funds from the Public Administration sector;951,439;458,700;372,119;119,498;1,122;
1.4) By origin of funds: Funds from the Higher Education sector;4,307;1,537;2,122;647;0;
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;52,107;28,686;9,445;12,986;990;
1.6) By origin of funds: Funds from the rest of the world;249,530;92,551;53,363;102,065;1,551;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);171,660;35,006;13,038;123,396;220;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;131,863;30,282;12,385;88,985;212;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;39,797;4,725;653;34,412;8;
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;41.8;57.5;52.9;39.8;72.7;
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;14.8;8.8;14.7;15.3;9.1;
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;24.5;46.0;36.8;22.3;18.2;
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;13.8;23.0;35.3;12.1;9.1;
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;19.0;28.3;44.1;17.1;27.3;
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;19.4;28.3;38.2;17.8;18.2;
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;15.3;10.6;10.3;16.0;9.1;
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;41.3;40.7;39.7;41.4;36.4;
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;51.2;62.8;51.5;50.2;63.6;
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;20.0;19.5;19.1;20.1;18.2;
Notes:
1) Data referring to all companies and organisations that carry out internal R&D in Biotechnology.
 2) ' .'= numeric data equal to zero not resulting from rounding
 3) FTE: Full-Time Equivalence
Source: National Statistics Institute